

## Amendments

### Amendments to the Claims

1. (Previously presented) A method of preparing a composition, said composition comprising <sup>an isolated</sup> a heterologous gene product and a pharmaceutically acceptable carrier, said method comprising the steps of:

- (a) inserting a gene coding for the <sup>isolated</sup> heterologous gene product into an expression vector;
- (b) transforming said expression vector into a commensal *Neisseria*;
- (c) expressing said heterologous gene product in said commensal *Neisseria*;
- (d) obtaining said heterologous gene product from the *Neisseria* of (c); and <sup>how is this product obtained by isolating...</sup>
- (e) combining the <sup>isolated</sup> heterologous gene product of (d) with the pharmaceutically acceptable carrier, wherein said <sup>isolated</sup> heterologous gene product is selected from (1) a product of a gene of a non-*Neisserial* organism and (2) a product of a gene of a pathogenic *Neisseria*.

2. (Original) The method of claim 1, wherein said commensal *Neisseria* is selected from the group consisting of *N. cinerea*, *N. lactamica*, *N. elongata*, *N. flava*, *N. flavescens*, *N. polysaccharea*, *N. sicca*, *N. mucosa*, *N. perflava* and *N. subflava*.

3. (Previously presented) The method of claim 1, the heterologous gene product is the product of a gene from a pathogenic *Neisseria*.

LAB

4. (Previously presented) The method of claim 3, wherein the heterologous gene product is selected from the group consisting of transferrin binding protein; a Cu,Zn-SOD; an NspA; a porin; an outer membrane protein and fragments thereof.

should  
be  
commas  
no  
semi-colons

5. (Original) The method of claim 1, wherein said obtaining comprises:

- (i) suspending said commensal *Neisseria* cells in the presence of detergent; and  
(ii) incubating the suspension so as to extract a protein fraction from the cells.

how do you  
know which  
protein fraction  
you're  
extracting?

6. (Previously presented) The method of claim 5, wherein the protein fraction is of molecular weight 50 kDa or lower when measured by SDS-PAGE.

7. (Previously presented) The method of claim 5, wherein the protein fraction is of molecular weight from 40 kDa to 90 kDa when measured by SDS-PAGE.

8. (Previously presented) The method of claim 5, wherein the protein fraction is of molecular weight at least 80 kDa when measured by SDS-PAGE.

9-18. (Canceled).

19. (Original) A composition obtained by the method of claim 1.

20-21. (Canceled).

22. (New) A method according to claim 1, wherein step (d) comprises obtaining  
an outer membrane vesicle and wherein the outer membrane vesicle comprises said  
heterologous gene product.

23. (New) A composition obtained by the method of claim 22.

*Non-elected not same invention as cl 1-8*

24. (New) A method of preparing a composition, said composition comprising a  
heterologous product, a commensal *Neisseria* and a pharmaceutically acceptable carrier, said  
method comprising the steps of:

*not clear  
preamble  
3 compounds  
part(d) only  
has 2*

- isolated*
- (a) inserting a gene coding for the heterologous gene product into an expression  
vector;
- (b) transforming said expression vector into a commensal *Neisseria*;
- (c) expressing said heterologous gene product in said commensal *Neisseria*;
- (d) combining the commensal *Neisseria* of (c) with the pharmaceutically  
acceptable carrier, wherein said heterologous gene product is selected from  
the group consisting of (1) a product of a gene of a non-neisserial organism,  
and (2) a product of a gene of a pathogenic *Neisseria*.

*obj  
Neisserial  
←*

25. (New) A composition obtained by the method of claim 24.